Do you know the cardiovascular health related to overweight and obesity? These are the parameters you have to measure!
It is well-known that obesity is strongly related to hypertension and cardiovascular disease risk, also in apparently healthy subjects. However, the simple measure of body weight could underestimate the risk, because not always related to visceral obesity, the most dangerous form of obesity. What are the most practical index that we can use to estimate the cardiovascular disease risk in obese subjects?

Waist circumference (WC): Normal if < 94 cm for Caucasian men and < 80cm for Caucasian women

Waist/Hip ratio: normal if < 0,95 in men and if < 0,8 in women

Body Mass Index (kg/m2): Classification

< 18,5 Underweight
> 18,5 (< 25,0) Normal
> 25,0 (< 30,0) Overweight
> 30,0 (< 35,0) I class obesity
> 35,0 (< 40,0) II class obesity
> 40,0 III class obesity

 

Body Shape Index (ABSI) = WC/(BMI(2/3)×height(1/2))

Death rates increased approximately exponentially with above average baseline ABSI

Basal Metabolic Rate (Kcal/m2/hour): Fleisch formula, Inversely related to risk to develop obesity

BMR (Men) = 24 * BSA * {35,5 - 0,064 * [age (years) - 20]}
BMR (Women) = 24 * BSA * {38 - 0,073 * [age (years) - 20]}
dove Body Area Surface (BAS, m2) = [(Height (cm) X Weight (kg) / 3600)]1/2

Index of central obesity ratio of waist circumference and height (negative if >0.5)

Visceral Adiposity Index (VAI)

Males: WC/ [39.68 + (1.88 × BMI)] × (TG/1.03) × (1.31/HDL);
Females: WC/[36.58 + (1.89 × BMI)] × (TG/0.81) × (1.52/HDL)
where both TG and HDL levels are expressed in mMol/L

Normality cut-off are 2.52 for patients under 30 years, 2.23 for those aged between 30 and 42 years, 1.92 between 42 and 52 years, 1.93 between 52 and 66 years and 2.00 for patients over 66 years.

Deep Dive for registered Doctors

This article has additional & reserved content for registered doctors. Please log in or create a new profile to access this insights.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Healthcare professionals and consumers are asked to report any suspected adverse reactions via the national reporting system.

All information on this site does not in any way replace the judgment of a specialist physician, the only one authorized to make advice and to express a medical opinion.

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of this site have already been set. To find out more about the cookies we use and how to delete them, see our privacy policy.